Comparative Pharmacology
Head-to-head clinical analysis: AGGRASTAT versus ZONTIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRASTAT versus ZONTIVITY.
AGGRASTAT vs ZONTIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirofiban is a reversible antagonist of glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by blocking fibrinogen binding.
ZONTIVITY (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist that inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. It does not directly inhibit thrombin activity but blocks thrombin-mediated platelet activation.
A loading dose of 25 mcg/kg administered intravenously over 3 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. For patients with severe renal impairment (GFR <30 mL/min), the maintenance infusion rate is reduced to 0.075 mcg/kg/min.
1 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life: ~2 hours; clinical context: requires continuous IV infusion for sustained antiplatelet effect
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal: 65% unchanged drug; biliary/fecal: minimal (<5%)
Primarily as unchanged drug via renal excretion (approximately 80%) and fecal/biliary elimination (approximately 20%).
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent